Allogene Therapeutics, Inc.
ALLO · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 156.00K | -14.14M | -335.54M | -340.41M | -2.38 |
| 2023 FY | 95.00K | 95.00K | -327.74M | -327.27M | -2.09 |
| 2024 FY | 22.00K | 22.00K | -273.20M | -257.59M | -1.32 |
| 2025 FY | — | -12.36M | -206.93M | -190.89M | -0.87 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 821.58M | 154.70M | 61.90M | 101.12M | 666.88M |
| 2023 FY | 642.84M | 130.60M | 83.16M | 95.12M | 512.23M |
| 2024 FY | 548.71M | 126.53M | 75.22M | 90.76M | 422.18M |
| 2025 FY | 415.91M | 123.36M | 51.69M | 83.25M | 292.54M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -220.52M | -5.19M | -225.71M | — | -111.41M |
| 2023 FY | -237.73M | -1.52M | -239.25M | — | 21.25M |
| 2024 FY | -200.30M | -694.00K | -200.99M | — | -7.94M |
| 2025 FY | -149.25M | -386.00K | -149.63M | — | -23.53M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 900.39M | 939.61M | — | — | — |
| 2023 FY | 503.75M | 515.72M | — | — | — |
| 2024 FY | 414.95M | 430.49M | — | — | — |
| 2025 FY | 302.25M | 333.82M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | -40.16M | -56.82M | -50.94M | -0.23 |
| 2025 Q3 | — | -31.16M | -44.90M | -41.40M | -0.19 |
| 2025 Q4 | — | -3.06M | -42.40M | -38.81M | -0.17 |
| 2026 Q1 | — | -2.87M | -46.09M | -42.61M | -0.18 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 470.59M | 126.03M | 52.33M | 79.24M | 344.56M |
| 2025 Q3 | 439.77M | 124.44M | 37.82M | 85.14M | 315.33M |
| 2025 Q4 | 415.91M | 123.36M | 51.69M | 83.25M | 292.54M |
| 2026 Q1 | 395.96M | 117.08M | 30.31M | 81.05M | 278.88M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -39.03M | -44.00K | -39.07M | — | 9.88M |
| 2025 Q3 | -29.69M | -243.00K | -29.93M | — | -14.52M |
| 2025 Q4 | -27.60M | — | -27.60M | — | 13.87M |
| 2026 Q1 | -12.91M | -9.00K | -12.92M | — | -21.38M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 247.39M | 274.30M | — | — | — |
| 2025 Q3 | 275.33M | 322.65M | — | — | — |
| 2025 Q4 | 302.25M | 333.82M | — | — | — |
| 2026 Q1 | 586.31M | 637.05M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |